Celanese Corporation (CE) and Secarna Pharmaceuticals GmbH & Co. KG recently established a research collaboration to create long-acting implants delivering antisense oligonucleotides ("ASO").ASOs are synthetic compounds that target specific messenger RNA to block the creation of proteins involved in the progression of a variety of diseases, including cardiometabolic, central nervous system, oncologic and uncommon disorders. Antisense therapy is a novel, commercially validated therapeutic method. However, it ...